DNA immunization with HBsAg-based particles expressing a B cell epitope of amyloid β-peptide attenuates disease progression and prolongs survival in a mouse model of Alzheimer's disease

Vaccine

Volumn 30, Issue 9, 2012, Pages 1650-1658

  Olkhanud, Purevdorj B ^a   Mughal, Mohammed ^a   Ayukawa, Koichi ^a   Malchinkhuu, Enkhzol ^a   Bodogai, Monica ^a   Feldman, Neil ^a   Rothman, Sarah ^a   Lee, Jong Hwan ^a   Chigurupati, Srinivasulu ^a   Okun, Eitan ^a   Nagashima, Kunio ^b   Mattson, Mark P ^a   Biragyn, Arya ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

A ; Alzheimer's disease vaccine; Life span; Old age

Indexed keywords

ALZHEIMER DISEASE VACCINE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-11]; HEPATITIS B SURFACE ANTIGEN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; B LYMPHOCYTE; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE COURSE; DNA IMMUNIZATION; LIFE EXTENSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

AGE FACTORS; ALZHEIMER DISEASE; ALZHEIMER VACCINES; AMYLOID BETA-PEPTIDES; ANIMALS; DISEASE MODELS, ANIMAL; EPITOPES, B-LYMPHOCYTE; HEPATITIS B SURFACE ANTIGENS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; T-LYMPHOCYTES; VACCINES, DNA;

EID: 84862777017     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.12.136     Document Type: Article

References (49)

1. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 2004, 430(August (7000)):631-639.
2. Golde T.E., Dickson D., Hutton M. Filling the gaps in the abeta cascade hypothesis of Alzheimer's disease. Current Alzheimer Research 2006, 3(December (5)):421-430.
3. Jin M., Shepardson N., Yang T., Chen G., Walsh D., Selkoe D.J. Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proceedings of the National Academy of Sciences of the United States of America 2011, 108(April (14)):5819-5824.
4. Monsonego A., Zota V., Karni A., Krieger J.I., Bar-Or A., Bitan G., et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. The Journal of Clinical Investigation 2003, 112(August (3)):415-422.
5. Xie J., Brayne C., Matthews F.E. Survival times in people with dementia: analysis from population based cohort study with 14 year follow-up. BMJ 2008, 336(February (7638)):258-262.
6. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372(July (9634)):216-223.
7. Bard F., Cannon C., Barbour R., Burke R.L., Games D., Grajeda H., et al. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nature Medicine 2000, 6(August (8)):916-919.
8. Ryan D.A., Mastrangelo M.A., Narrow W.C., Sullivan M.A., Federoff H.J., Bowers W.J. A beta-directed single-chain antibody delivery via a serotype-1 AAV vector improves learning behavior and pathology in Alzheimer's disease mice. Molecular Therapy 2010, 18(August (8)):1471-1481.
9. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., et al. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 2000, 408(December (6815)):982-985.
10. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400(July (6740)):173-177.
11. Movsesyan N., Ghochikyan A., Mkrtichyan M., Petrushina I., Davtyan H., Olkhanud P.B., et al. Reducing AD-like pathology in 3xTg-AD mouse model by DNA epitope vaccine - a novel immunotherapeutic strategy. PLoSONE 2008, 3(5):e2124.
12. Bombois S., Maurage C.A., Gompel M., Deramecourt V., Mackowiak-Cordoliani M.A., Black R.S., et al. Absence of beta-amyloid deposits after immunization in Alzheimer disease with Lewy body dementia. Archives of Neurology 2007, 64(April (4)):583-587.
13. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64(May (9)):1553-1562.
14. Castellino F., Boucher P.E., Eichelberg K., Mayhew M., Rothman J.E., Houghton A.N., et al. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. Journal of Experimental Medicine 2000, 191(June (11)):1957-1964.
15. Hock C., Konietzko U., Papassotiropoulos A., Wollmer A., Streffer J., von Rotz R.C., et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nature Medicine 2002, 8(November (11)):1270-1275.
16. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61(July (1)):46-54.
17. Monsonego A., Imitola J., Petrovic S., Zota V., Nemirovsky A., Baron R., et al. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(March (13)):5048-5053.
18. Monsonego A., Maron R., Zota V., Selkoe D.J., Weiner H.L. Immune hyporesponsiveness to amyloid beta-peptide in amyloid precursor protein transgenic mice: implications for the pathogenesis and treatment of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(August (18)):10273-10278.
19. Bard F., Barbour R., Cannon C., Carretto R., Fox M., Games D., et al. Epitope and isotype specificities of antibodies to beta-amyloid peptide for protection against Alzheimer's disease-like neuropathology. Proceedings of the National Academy of Sciences of the United States of America 2003, 100(February (4)):2023-2028.
20. Lee M., Bard F., Johnson-Wood K., Lee C., Hu K., Griffith S.G., et al. Abeta42 immunization in Alzheimer's disease generates Abeta N-terminal antibodies. Annals of Neurology 2005, 58(September (3)):430-435.
21. Nicoll J.A., Barton E., Boche D., Neal J.W., Ferrer I., Thompson P., et al. Abeta species removal after abeta42 immunization. Journal of Neuropathology and Experimental Neurology 2006, 65(November (11)):1040-1048.
22. Kumar R., Burns E.A. Age-related decline in immunity: implications for vaccine responsiveness. Expert Review of Vaccines 2008, 7(May (4)):467-479.
23. Webster R.G. Immunity to influenza in the elderly. Vaccine 2000, 18(February (16)):1686-1689.
24. Bayer A.J., Bullock R., Jones R.W., Wilkinson D., Paterson K.R., Jenkins L., et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology 2005, 64(January (1)):94-101.
25. Zhao Q., Wang Y., Freed D., Fu T.M., Gimenez J.A., Sitrin R.D., et al. Maturation of recombinant hepatitis B virus surface antigen particles. Human Vaccines 2006, 2(July-August (4)):174-180.
26. Milich D.R., Peterson D.L., Schodel F., Jones J.E., Hughes J.L. Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent. Journal of Virology 1995, 69(May (5)):2776-2785.
27. Oddo S., Caccamo A., Shepherd J.D., Murphy M.P., Golde T.E., Kayed R., et al. Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 2003, 39(July (3)):409-421.
28. Liu D., Pitta M., Lee J.H., Ray B., Lahiri D.K., Furukawa K., et al. The KATP channel activator diazoxide ameliorates amyloid-beta and tau pathologies and improves memory in the 3xTgAD mouse model of Alzheimer's disease. Journal of Alzheimer's Disease 2010, 22(2):443-457.
29. Ruffini P.A., Neelapu S.S., Kwak L.W., Biragyn A. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Haematologica 2002, 87(9):989-1001.
30. Bogen B., Lambris J.D. Minimum length of an idiotypic peptide and a model for its binding to a major histocompatibility complex class II molecule. EMBO Journal 1989, 8:1947-1952.
31. Schiavo R., Baatar D., Olkhanud P., Indig F.E., Restifo N., Taub D., et al. Chemokine receptor targeting efficiently directs antigens to MHC class I pathways and elicits antigen-specific CD8+ T-cell responses. Blood 2006, 107(12):4597-4605.
32. Ruffini P.A., Biragyn A., Coscia M., Harvey L.K., Cha S.C., Bogen B., et al. Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. Journal of Leukocyte Biology 2004, 76(1):77-85.
33. Borisova G., Arya B., Dislers A., Borschukova O., Tsibinogin V., Skrastina D., et al. Hybrid hepatitis B virus nucleocapsid bearing an immunodominant region from hepatitis B virus surface antigen. Journal of Virology 1993, 67(June 6):3696-3701.
34. Gallagher D., Coen R., Kilroy D., Belinski K., Bruce I., Coakley D., et al. Anxiety and behavioural disturbance as markers of prodromal Alzheimer's disease in patients with mild cognitive impairment. International Journal of Geriatric Psychiatry 2011, 26(February (2)):166-172.
35. Dawson G.R., Tricklebank M.D. Use of the elevated plus maze in the search for novel anxiolytic agents. Trends in Pharmacological Sciences 1995, 16(February (2)):33-36.
36. Monsonego A., Imitola J., Zota V., Oida T., Weiner H.L. Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Th1 cells. Journal of Immunology 2003, 171(September (5)):2216-2224.
37. Ghochikyan A. Rationale for peptide and DNA based epitope vaccines for Alzheimer's disease immunotherapy. CNS & Neurological Disorders Drug Targets 2009, 8(April (2)):128-143.
38. Davtyan H., Mkrtichyan M., Movsesyan N., Petrushina I., Mamikonyan G., Cribbs D.H., et al. DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Therapy 2010, 17(February (2)):261-271.
39. Bach P., Tschape J.A., Kopietz F., Braun G., Baade J.K., Wiederhold K.H., et al. Vaccination with Abeta-displaying virus-like particles reduces soluble and insoluble cerebral Abeta and lowers plaque burden in APP transgenic mice. Journal of Immunology 2009, 182(June (12)):7613-7624.
40. Chackerian B., Rangel M., Hunter Z., Peabody D.S. Virus and virus-like particle-based immunogens for Alzheimer's disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine 2006, 24(September (37-39)):6321-6331.
41. Lemere C.A., Masliah E. Can Alzheimer disease be prevented by amyloid-beta immunotherapy?. Nature Reviews Neurology 2010, 6(February (2)):108-119.
42. Mouri A., Noda Y., Hara H., Mizoguchi H., Tabira T., Nabeshima T. Oral vaccination with a viral vector containing Abeta cDNA attenuates age-related Abeta accumulation and memory deficits without causing inflammation in a mouse Alzheimer model. FASEB Journal 2007, 21(July (9)):2135-2148.
43. Maier M., Seabrook T.J., Lemere C.A. Modulation of the humoral and cellular immune response in Abeta immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT(R192G). Vaccine 2005, 23(October (44)):5149-5159.
44. Bacskai B.J., Kajdasz S.T., McLellan M.E., Games D., Seubert P., Schenk D., et al. Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy. Journal of Neuroscience 2002, 22(September (18)):7873-7878.
45. Boche D., Zotova E., Weller R.O., Love S., Neal J.W., Pickering R.M., et al. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain 2008, 131(December (Pt 12)):3299-3310.
46. Wilcock D.M., Rojiani A., Rosenthal A., Levkowitz G., Subbarao S., Alamed J., et al. Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. Journal of Neuroscience 2004, 24(July (27)):6144-6151.
47. Forster M.J., Morris P., Sohal R.S. Genotype and age influence the effect of caloric intake on mortality in mice. FASEB Journal 2003, 17(April (6)):690-692.
48. Alavez S., Vantipalli M.C., Zucker D.J., Klang I.M., Lithgow G.J. Amyloid-binding compounds maintain protein homeostasis during ageing and extend lifespan. Nature 2011, 472(April (7342)):226-229.
49. Wampler D.E., Lehman E.D., Boger J., McAleer W.J., Scolnick E.M. Multiple chemical forms of hepatitis B surface antigen produced in yeast. Proceedings of the National Academy of Sciences of the United States of America 1985, 82(October (20)):6830-6834.